1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs

Ähnliche Einträge

• 1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs
  von: Grace Zhao, et al.
  Veröffentlicht: (2023-11-01)
• 481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow
  von: Timothy C Wang, et al.
  Veröffentlicht: (2023-11-01)
• Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge
  von: Ryan S. Noyce, et al.
  Veröffentlicht: (2023-01-01)
• Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits
  von: Mayanka Awasthi, et al.
  Veröffentlicht: (2023-10-01)
• Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
  von: Mayanka Awasthi, et al.
  Veröffentlicht: (2023-11-01)